IBO — IMPACT BIOMEDICAL INC.
—
NYSE ·
Health Care ·
Pharmaceuticals ·
CIK 1834105 ·
Last close
$5.61
Market Cap
$604.88M
52W High
$10.51
52W Low
$4.68
ADV30
19,775
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 3,000 | 2,000 | -702,000 | -699,000 | 16,745,000 | 10,000 | 2,733,000 |
| Mar 2026 | 7,000 | — | -2,289,000 | -2,287,000 | 17,086,000 | 20,000 | 2,375,000 |
| Dec 2025 | 7,000 | -415,000 | -1,158,000 | 5,245,000 | 17,405,000 | 3,000 | 1,850,000 |
| Sep 2025 | 18,000 | 17,000 | -948,000 | -1,470,000 | 18,208,000 | 12,000 | 27,061,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-1,672,000
Investing CF
$1,000
Financing CF
$373,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.43
As of
2026-08-09
Balance + Analyst (yfinance extras)
Retained Earnings
$-51,794,000
Inventory
$63,000
Receivables
$199,000
ST Investments
—
EBIT TTM
$-14,934,000
Pretax Income TTM
$-15,456,000
Interest Exp TTM
$522,000
Analysts
—
Yahoo Snapshot (yfinance, live)
Total Revenue
$35,000
EBITDA
$-3,952,000
Free Cash Flow
$1,016,875
Enterprise Value
$52,855,332
Total Cash
$10,000
Total Debt
$0
Shares Out
107,821,231
Trailing EPS
$0.88
Book Value
$0.10
ROE
23.5%
ROA
-17.8%
Div Yield
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 32,000 | -4,270,000 | -11,838,000 | 17,405,000 | 1,850,000 | 12,609,000 | -1,890,000 |
| Dec 2024 | 0 | -3,397,000 | -24,708,000 | 20,290,000 | 13,053,000 | 4,259,000 | -2,854,000 |
| Dec 2023 | 0 | -4,028,000 | -4,336,000 | 44,633,000 | 16,371,000 | 25,222,000 | -2,851,000 |
| Dec 2022 | 50,000 | -3,404,000 | -7,051,000 | 46,497,000 | 13,828,000 | 29,558,000 | -2,242,000 |
| Dec 2021 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| SGMT | Sagimet Biosciences Inc. | $612.22M | $9.94 | — |
| AQST | Aquestive Therapeutics, Inc. | $596.18M | $4.75 | — |
| CRMD | CorMedix Inc. | $614.98M | $7.89 | — |
| PHAT | Phathom Pharmaceuticals, Inc. | $594.62M | $7.35 | — |
| CTMX | CytomX Therapeutics, Inc. | $586.15M | $2.69 | — |
News headlines (Yahoo Finance, 1h cache)
DSS, Inc. Announces Form F-4 Filing in Connection with Impact Biomedical’s Proposed Business Combination with Zoar Limited
2026-09-16 13:25 · Yahoo
Impact Biomedical Inc Announces Filing of Form F-4 Registration Statement in Connection with Proposed Merger with Zoar Ltd. (f/k/a Dr. Ashley’s Limited)
2026-09-16 13:20 · Yahoo
CORRECTED — Impact Biomedical Inc (NYSE: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Limited (f/k/a Dr Ashleys Limited)
2026-09-15 01:26 · Yahoo
Impact BioMedical Inc (NYSE American: IBO) Announces 1 for 12.62 Reverse Stock Split to Pursue Completion of Merger with Zoar Ltd. (previously Dr. Ashley’s Ltd.)
2026-09-11 20:05 · Yahoo
Impact BioMedical Inc. Reports Going Concern Audit Opinion in 2025 10-K Filing While Continuing Strategic Merger Plans
2026-04-03 17:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.